J. P. Johnson

发表

Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain.

D. Sutherlin, Jun Chen, D. Hackos, 2019, Journal of medicinal chemistry.

Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.

Shifeng Liu, R. Oballa, D. Sutherlin, 2016, ACS medicinal chemistry letters.

Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist

Jun Li, Christine Tam, Daniel F. Ortwine, 2015, Science.

Discovery of Acyl-sulfonamide Nav1.7 Inhibitors GDC-0276 and GDC-0310.

D. Sutherlin, Jun Chen, D. Hackos, 2021, Journal of medicinal chemistry.

Identification of aryl sulfonamides as novel and potent inhibitors of NaV1.5.

Angela Hussainkhel, J. Empfield, Jr., 2021, Bioorganic & medicinal chemistry letters.

Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.

R. DeVita, S. Decker, Matthew Waldbrook, 2019, Journal of medicinal chemistry.

Variable patterns of mutation density among NaV1.1, NaV1.2 and NaV1.6 point to channel-specific functional differences associated with childhood epilepsy

M. Hammer, Joseph Watkins, A. Encinas, 2020, PloS one.

Expanding the genotype-phenotype spectrum in SCN8A-related disorders

M. Demos, M. Hebbar, L. Armstrong, 2024, BMC neurology.

Expanding the genotype-phenotype spectrum in SCN8A-related disorders

M. Demos, M. Hebbar, M. Connolly, 2023, Research square.